Recall Z-2111-2023

Reason for recall

There is a potential risk for unintentional interaction of the Impella motor housing with the distal stent of a transcatheter aortic valve replacement (TAVR) resulting in destruction of the impeller blades. This has resulted in low flow from the damaged Impella system. Systemic embolization of the fractured impeller material is a possibility.

FDA-determined cause: Under Investigation by firm

Action taken

An URGENT: MEDICAL DEVICE CORRECTION (NOTIFICATION) dated 6/14/23 was sent to customers. RECOMMENDATIONS: Clinicians are cautioned to position the Impella system carefully in patients with TAVR, and to be aware of this potential interaction. In this situation, clinicians should avoid repositioning while the device is spinning and should turn the device to P0 during repositioning or any movement that could bring the outlet windows into proximity to the valve stent structures. If there is low flow observed in a patient implanted with a TAVR while on Impella heart pump support, you should consider damage of the impeller and replace the Impella pump as soon as possible. ACTIONS TO BE TAKEN BY CUSTOMER/USER " Product is NOT being removed from the field and does not need to be returned. " Review, complete all fields, sign, and return the attached business response form (BRF) on the last page of this letter to the Recall Coordinator identified in this document. " Forward this notice to anyone in your facility that needs to be informed (i.e., those who manage, transport, store, stock, or use the subject products). " If any of the subject products have been forwarded to another facility, contact that facility and provide them with this notice. " Post a copy of this notice in a visible area for awareness of this field safety notice. " As with any medical device, adverse reactions or quality problems experienced with the use of this product should be reported to the FDA s MedWatch Adverse Event Reporting Program using the link below: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting- program/reporting-serious-problems-fda At Abiomed, our priority is to our customers and their patients, and that includes the safe and effective use of our products. If you have questions or concerns regarding this notice, please contact (Shashi Thoutam) directly at +1(734) 262-6255 and/or your local clinical field staff. Thank you for your cooperation. Th